- |||||||||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Retrospective data, Journal, Adverse events: Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer. (Pubmed Central) - Nov 19, 2025
Although excess risks differed slightly between Black and White patients, overall differences were small. These findings highlight the need for monitoring and mitigation strategies for patients receiving ADT.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Observational data, P4 data, Journal: Therapeutic impact of leuprorelin acetate on spinal and bulbar muscular atrophy: pre- and post-marketing observational study. (Pubmed Central) - Nov 19, 2025
These findings highlight the value of leveraging patient registries and post-marketing real-world data to evaluate treatment efficacy in slowly progressive diseases, such as SBMA, where traditional randomized controlled trials are often limited by insufficient statistical power to detect therapeutic efficacy. They also underscore the need for innovative methodologies to assess post-approval drug performance, paving the way for improved clinical outcomes for neurodegenerative diseases.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Journal: Relugolix in treatment of prostate cancer: a review. (Pubmed Central) - Nov 17, 2025
Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities.
- |||||||||| Preclinical, Journal: Two cases of MACS due to PBMAH associated with an in vivo aberrant response to LHRH treated with leuprolide acetate. (Pubmed Central) - Nov 6, 2025
In both patients, morning serum cortisol levels remained elevated following 1 mg dexamethasone suppression test (DST) and 4 mg intravenous DST, while basal adrenocorticotropic hormone (ACTH) levels were suppressed...The first case involved a 69-year-old woman who exhibited significant increases in cortisol in response to luteinizing hormone-releasing hormone (LHRH; +142%), vasopressin (+66%) and metoclopramide (+98%)...In patients with MACS who have an aberrant cortisol response following LHRH stimulation, the long-acting GnRH agonist leuprolide acetate can be used to suppress endogenous LH production and improve hypercortisolism. A greater increase in cortisol secretion following LHRH stimulation and small response to the other stimuli could potentially be predictive of a better response to treatment with leuprolide acetate.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Journal: Self-assembled leuprolide-oleic acid nanoparticles encapsulating docetaxel for synergistic drug delivery. (Pubmed Central) - Nov 2, 2025
Furthermore, confocal microscopy confirmed the cellular uptake of the nanoparticles in both PC-3 and RAW 264.7 macrophage cells. Based on these findings, LOND, simultaneously releasing LEU, DTX, and fatty acids (such as OA), provides a promising drug delivery platform for triple synergy in the treatment of prostate cancer.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Optimization of aqueous remote loading of leuprolide in poly(lactic-co-glycolic acid) microspheres. (Pubmed Central) - Nov 2, 2025
The drug loading and EE were not strongly affected by porosity once above 50?%. Hence, by applying the theoretical analysis as described here, drug loading and EE can be manipulated to optimal levels by first monitoring quasi-equilibrium binding isotherms, indicating the potential for both general translational remote loading of therapeutic peptides and future applications for peptides with limited aqueous solubility and for encapsulation on the small scale.
- |||||||||| Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
When Therapy Leaves a Mark: A Case of Ribociclib-Induced Vitiligo Reversed with Abemaciclib (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2099;
This case contributes to the limited literature on CDK4/6 inhibitor-induced pigmentary changes. It underscores the need for clinical awareness of this rare toxicity and demonstrates that switching agents within the same drug class may offer symptom resolution without compromising cancer treatment.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Journal: Adverse Cardiovascular Outcomes of Individuals Treated with Androgen Deprivation Therapy. (Pubmed Central) - Oct 23, 2025
Relugolix was not associated with lower risk of MACE in our analysis. Strategies to optimize the cardiovascular management of patients receiving ADT are needed.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, leuprolide acetate for depot suspension / Generic mfg.
Journal: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. (Pubmed Central) - Oct 22, 2025
P3
Enzalutamide monotherapy was not superior to leuprolide alone in the analysis of overall survival. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).
- |||||||||| abiraterone acetate / Generic mfg.
Syndrome of Mineralocorticoid Excess with Abiraterone Use (Exhibit Hall, Convention Center) - Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_4068;
Case Description A 72-year-old man with past medical history of metastatic prostate cancer on leuprolide and abiraterone and hypertension presented from his primary care clinic with routine labs with recurrent hypokalemia to 2.8...Potassium levels stabilized after 2 days, and patient was discharge on spironolactone 150 mg in addition to his prednisone...Additionally, mineralocorticoid antagonists can be used to treat hypertension and hypokalemia . Mineralocorticoid antagonist used to suppresses aldosterone while awaiting effects of prednisone therapy in reducing ACTH drive.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Oct 16, 2025
P4, N=10, Completed,
Mineralocorticoid antagonist used to suppresses aldosterone while awaiting effects of prednisone therapy in reducing ACTH drive. Recruiting --> Completed | N=228 --> 10 | Trial completion date: Mar 2028 --> Jul 2025 | Trial primary completion date: Mar 2028 --> Jul 2025
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Clinical, Retrospective data, Review, Journal, HEOR: Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes. (Pubmed Central) - Oct 15, 2025
Oral relugolix significantly improves EHP-30 pain domain scores and patient response rates in endometriosis, particularly when compared to placebo. It also positively impacts emotional well-being, social support, and self-image.
- |||||||||| Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Journal: Relugolix in prostate cancer therapy: Clinical evidence and practical considerations. (Pubmed Central) - Oct 6, 2025
It offers rapid and sustained testosterone suppression, potential cardiovascular benefits, and an alternative to injectable therapies. Long-term adherence, the use of combination treatments and related drug-drug interactions require further investigation.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
COMPLEXITY IN THE DIAGNOSIS OF DYSMENORRHEA: DIAPHRAGMATIC ENDOMETRIOSIS IN A YOUNG FEMALE () - Oct 6, 2025 - Abstract #FIGO2025FIGO_2623;
Progesterone only contraceptives...Exclusion criteria: A prospective participant will not be eligible for enrolment if they meet any of the following exclusion criteria: Current use of tranexamic acid (eg Lysteda This case illustrates the severity of extra-pelvic endometriosis and highlights the importance of early recognition to provide appropriate treatment and prevent known disease complications.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: Kisspeptin Administration Subcutaneously to Patients With IHH (clinicaltrials.gov) - Oct 3, 2025
P2, N=36, Recruiting,
Available on Saturday, November 08, 2025 at 03:15pm CDT. Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Jun 2027 --> May 2028
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Immune landscape of cardiovascular mortality in primary prostate cancer patients following leuprolide treatment, a non-canonical immunotherapy (Poster Hall (Exhibit Halls AB); Virtual) - Oct 3, 2025 - Abstract #SITC2025SITC_1078;
To dissect the mechanisms underlining CVD risk, we plan to assess plaque formation propensity of myeloid cells present in primary PCa, explore the impact of a novel leptin inhibitor, and correlate these changes with angiographic coronary plaque progression.Ethics Approval Ethics approval was obtained from Emory IRB (ID: RAD5484-21) and Emory IACUC (Protocol number: 201700866)Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
- |||||||||| Visanne (dienogest) / Mochida, Bayer
Review, Journal: Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain. (Pubmed Central) - Sep 27, 2025
In the absence of a clear hierarchy of efficacy, the optimal therapeutic choice is not determined by potency, but by a collaborative process in which patient values and tolerance for specific adverse effects guide selection. This review provides a framework to facilitate this shared decision-making (SDM) in clinical practice.
- |||||||||| Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Trial completion date: REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov) - Sep 23, 2025
P2, N=94, Active, not recruiting,
Small subgroup sizes and low event numbers should be considered when interpreting results.SEPs Time to:Combo (n=355) Events (n); HR (95% CI)L alone (n=358) Trial completion date: Jun 2025 --> Dec 2025
- |||||||||| Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
Addition of 177 Lu-PSMA-617 in the treatment of hormone sensitive metastatic prostate cancer: a prospective pilot study (e-Poster Area) - Sep 12, 2025 - Abstract #EANM2025EANM_2314;
Materials and Methods Hormone sensitive metastatic prostate cancer patients on androgen deprivation therapy, and cannot tolerate docetaxel were included...Results Of the 8 patients recruited (A-H), 3 underwent surgical castration (B,C,E), 4 received medical ADT (Leuprolide)...Patient H awaits histopathological confirmation of prostate cancer for the start of ADT and abiraterone...A longer follow up, addition of a comparator/control arm and response assessment imaging would address the shortcomings of this pilot study. In line with our study, further research in the direction of optimal scheduling, sequencing and combination of Lu-177 PSMA therapy are promising prospects.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Journal: Precocious Puberty and GnRH analogs: Current treatment practices and perspectives amongst US pediatric endocrinologists. (Pubmed Central) - Sep 8, 2025
Despite having similar constituents and bioavailability, there are substantial cost differences between the pediatric and adult formulations and lack of evidence for safe use of these formulations in children. The survey-based analysis highlights the challenges faced by prescribers while reflecting on areas where further research is needed to provide evidence-based practice guidelines for pediatric endocrinologists.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, leuprolide acetate for depot suspension / Generic mfg.
Journal: Late-onset Leber's hereditary optic neuropathy and antiandrogens for prostate cancer: is there a causative link? (Pubmed Central) - Sep 4, 2025
Recent evidence suggests a protective effect of estrogens in increasing mitochondrial biogenesis (and mtDNA copy number), partially explaining the gender bias of the disease, while the role of androgens is yet to be fully understood. Considering the effect of the ADT on circulating hormonal levels and their reciprocal interactions, we hypothesize that in a context of already low estrogens levels due to GnRH analogue, the block of androgens receptors by Leuprolide further imbalance the estrogens to androgens ratio and eventually trigger the disease.
- |||||||||| Paraneoplastic Cholestatic Hepatitis in Prostate Cancer: A Rare Presentation of Stauffer Syndrome (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_6585;
Given concern for drug-induced liver injury, tadalafil and atorvastatin were stopped, but jaundice worsened...Leuprolide was started for androgen deprivation and ursodeoxycholic acid for symptomatic relief...Though a diagnosis of exclusion, paraneoplasia should be considered in cases of unexplained cholestasis in patients with malignancies. Early recognition is critical as appropriate oncologic management can lead to resolution of hepatic dysfunction and improved patient outcomes.Figure: 1A - MRI showing normal liver architecture without enlargement or lesions1B - MRI showing prostate concerning for malignancyFigure: Liver biopsy showing cholestatic pattern of hepatitis
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Rare Case of Cholestatic Stauffer's Syndrome in the Setting of Prostate Cancer (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_4363;
Lupron was initiated, but other antiandrogens were avoided due to risk of further liver injury...doi:10.4166/kjg.2021.059Figure: Figure 1. CT shows enlarged prostate, parailiac and aortocaval lymphadenopathy, hepatomegaly with no obstruction, and sclerotic lesions in the pelvis
- |||||||||| Kisqali (ribociclib) / Novartis
Atypical Presentation of Metastatic Breast Cancer in a 44-Year-Old Female: A Case Report (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_2596;
This case underscores the diagnostic challenge when faced with atypical breast cancer presentations and emphasizes the importance of including breast cancer in the differential when radiographic and endoscopic evaluation is consistent with metastatic disease. Figure: Endoscopic image of nodules located at the pylorusFigure: Endoscopic image of nodules located in the duodenal bulb
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
A Rare Case of Metastatic Prostate Cancer Causing Obstructive Jaundice (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_790;
Understanding this should guide clinical decision making and patient goals of care discussions.Figure: Figure 1. CT abdomen/pelvis with IV contrast revealed severe intra- and extrahepatic bile duct dilation with obstruction from adenopathy.Figure: Figure 2.CT abdomen/pelvis with IV contrast revealed extensive bulky retroperitoneal and gastrohepatic adenopathy with bilateral pelvic adenopathy.
|
